MicroRNA-34a is dispensable for p53 function as teratogenesis inducer

Archives of Toxicology

Volumn 88, Issue 9, 2014, Pages 1749-1763

  Mor, Eyal ^a   He, Lin ^b   Torchinsky, Arkady ^a   Shomron, Noam ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Development; Limbs; microRNA; miR 34; miRNA; p53; Teratogens

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GAS1 PROTEIN; MICRORNA; MICRORNA 34A; MICRORNA 34C; PROTEIN P53; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; AZACITIDINE; DECITABINE; MIRN34 MICRORNA, MOUSE; MIRN34 MICRORNA, RAT; TERATOGENIC AGENT;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DEVELOPMENTAL STAGE; EMBRYO; FEMALE; FORELIMB; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENOTYPE; HINDLIMB; HUMAN; HUMAN CELL; LIMB BUD; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTO ONCOGENE; RAT; REGULATORY MECHANISM; TERATOGENESIS; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; CONGENITAL MALFORMATION; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; FETUS DEVELOPMENT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOTE; INSTITUTE FOR CANCER RESEARCH MOUSE; KNOCKOUT MOUSE; LIMB MALFORMATION; METABOLISM; PREGNANCY; SPRAGUE DAWLEY RAT;

MUS; RATTUS;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; AZACITIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; FETAL DEVELOPMENT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HETEROZYGOTE; LIMB BUDS; LIMB DEFORMITIES, CONGENITAL; MALE; MICE, INBRED ICR; MICE, KNOCKOUT; MICRORNAS; PREGNANCY; RATS, SPRAGUE-DAWLEY; TERATOGENS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84906212554     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-014-1223-9     Document Type: Article

References (60)

1. Bae Y, Yang T, Zeng HC, Campeau PM, Chen Y, Bertin T, Dawson BC, Munivez E, Tao J, Lee BH (2012) miRNA-34c regulates Notch signaling during bone development. Hum Mol Genet 21(13):2991-3000
2. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136(2):215-233
3. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C (1995) Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376(6543):768-771
4. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, MacDougald OA, Cho KR, Fearon ER (2007) p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17(15):1298-1307 (Pubitemid 47176893)
5. Branch S, Francis BM, Brownie CF, Chernoff N (1996) Teratogenic effects of the demethylating agent 5-aza-2′-deoxycytidine in the Swiss Webster mouse. Toxicology 112(1):37-43 (Pubitemid 26276039)
6. Branch S, Chernoff N, Brownie C, Francis BM (1999) 5-AZA-2′- deoxycytidine-induced dysmorphogenesis in the rat. Teratog Carcinog Mutagen 19(5):329-338
7. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26(5):745-752 (Pubitemid 46856245)
8. Chen F, Hu SJ (2012) Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review. J Biochem Mol Toxicol 26(2):79-86
9. Chen X, Hu H, Guan X, Xiong G, Wang Y, Wang K, Li J, Xu X, Yang K, Bai Y (2012) CpG island methylation status of miRNAs in esophageal squamous cell carcinoma. Int J Cancer 130(7):1607-1613
10. Choi YJ, Lin CP, Ho JJ, He X, Okada N, Bu P, Zhong Y, Kim SY, Bennett MJ, Chen C, Ozturk A, Hicks G, Hannon GJ, He L (2011) miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat Cell Biol 13(11):1353-1360
11. Concepcion CP, Han YC, Mu P, Bonetti C, Yao E, D'Andrea A, Vidigal JA, Maughan WP, Ogrodowski P, Ventura A (2012) Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet 8(7):e1002797
12. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY (2007) MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 67(18):8433-8438 (Pubitemid 47437414)
13. Feng Z, Zhang C, Wu R, Hu W (2011) Tumor suppressor p53 meets microRNAs. J Mol Cell Biol 3(1):44-50
14. Fleiss JL (1981) Statistical methods for rates and proportions. Wiley, New York
15. Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19(1):92-105
16. Gueta K, Molotski N, Gerchikov N, Mor E, Savion S, Fein A, Toder V, Shomron N, Torchinsky A (2010) Teratogen-induced alterations in microRNA-34, microRNA-125b and microRNA-155 expression: correlation with embryonic p53 genotype and limb phenotype. BMC Dev Biol 10:20
17. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ (2007) A microRNA component of the p53 tumour suppressor network. Nature 447(7148):1130-1134 (Pubitemid 47014436)
18. Hermeking H (2010) The miR-34 family in cancer and apoptosis. Cell Death Differ 17(2):193-199
19. Hiroki E, Suzuki F, Akahira J, Nagase S, Ito K, Sugawara J, Miki Y, Suzuki T, Sasano H, Yaegashi N (2012) MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma. Int J Cancer 131(4):E395-E404
20. Hornstein E, Shomron N (2006) Canalization of development by microRNAs. Nat Genet 38(Suppl):S20-S24
21. Huang DW, Sherman BT, Lempicki RA (2009a) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37(1):1-13
22. Huang DW, Sherman BT, Lempicki RA (2009b) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44-57
23. Inouye M (1976) Differential staining of cartilage and bone in fetal mouse skeleton by Alcian blue and Alizarin red S. Congenit Anom 16:171-173
24. Irizarry RA, Ooi SL, Wu Z, Boeke JD (2003) Use of mixture models in a microarray-based screening procedure for detecting differentially represented yeast mutants. Stat Appl Genet Mol Biol 2(1):1002
25. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA (1994) Tumor spectrum analysis in p53- mutant mice. Curr Biol 4(1):1-7
26. Jain AK, Barton MC (2012) Unmet expectations: miR-34 plays no role in p53-mediated tumor suppression in vivo. PLoS Genet 8(7):e1002859
27. Kalimutho M, Di Cecilia S, Del Vecchio BG, Roviello F, Sileri P, Cretella M, Formosa A, Corso G, Marrelli D, Pallone F, Federici G, Bernardini S (2011) Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br J Cancer 104(11):1770-1778
28. Karpf AR, Moore BC, Ririe TO, Jones DA (2001) Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2?-deoxycytidine. Mol Pharmacol 59(4):751-757 (Pubitemid 32274003)
29. Krol J, Loedige I, Filipowicz W (2010) The widespread regulation of microRNA biogenesis, function and decay. Nat Rev 11(9):597-610
30. Lane D, Levine A (2010) p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol 2(12):a000893
31. Lee CS, May NR, Fan CM (2001) Transdifferentiation of the ventral retinal pigmented epithelium to neural retina in the growth arrest specific gene 1 mutant. Dev Biol 236(1):17-29
32. Lee HY, Inselman AL, Kanungo J, Hansen DK (2012) Alternative models in developmental toxicology. Syst Biol Reprod Med 58(1):10-22
33. Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, Zheng X (2009) miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 275(1):44-53
34. Lim LP, Glasner ME, Yekta S, Burge CB, Bartel DP (2003) Vertebrate microRNA genes. Science 299(5612):1540 (Pubitemid 36297696)
35. Liu C, Zhou C, Gao F, Cai S, Zhang C, Zhao L, Zhao F, Cao F, Lin J, Yang Y, Ni J, Jia J, Wu W, Zhou L, Cui J, Zhang W, Li B, Cai J (2011) MiR-34a in age and tissue related radio-sensitivity and serum miR-34a as a novel indicator of radiation injury. Int J Biol Sci 7(2):221-233
36. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J, Hermeking H (2008) Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7(16):2591-2600
37. Martinelli DC, Fan CM (2007) The role of Gas1 in embryonic development and its implications for human disease. Cell Cycle 6(21):2650-2655 (Pubitemid 350224048)
38. Mazar J, Khaitan D, DeBlasio D, Zhong C, Govindarajan SS, Kopanathi S, Zhang S, Ray A, Perera RJ (2011) Epigenetic regulation of microRNA genes and the role of miR-34b in cell invasion and motility in human melanoma. PLoS ONE 6(9):e24922
39. Mirkes PE (2008) Cell death in normal and abnormal development. Congenit Anom 48(1):7-17
40. Nakamura T, Sakai K, Nakamura T, Matsumoto K (2011) Hepatocyte growth factor twenty years on: much more than a growth factor. J Gastroenterol Hepatol 26(Suppl 1):188-202
41. Nalls D, Tang SN, Rodova M, Srivastava RK, Shankar S (2011) Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS ONE 6(8):e24099
42. Pekar O, Molotski N, Savion S, Fein A, Toder V, Torchinsky A (2007) p53 regulates cyclophosphamide teratogenesis by controlling caspases 3, 8, 9 activation and NF-kappaB DNA binding. Reproduction 134(2):379-388 (Pubitemid 47278810)
43. Raver-Shapira N, Oren M (2007) Tiny actors, great roles: microRNAs in p53′s service. Cell Cycle 6(21):2656-2661
44. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M (2007) Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26(5):731-743
45. Rogers JM, Francis BM, Sulik KK, Alles AJ, Massaro EJ, Zucker RM, Elstein KH, Rosen MB, Chernoff N (1994) Cell death and cell cycle perturbation in the developmental toxicity of the demethylating agent, 5-aza-2′-deoxycytidine. Teratology 50(5):332-339
46. Rosen MB, Chernoff N (2002) 5-Aza-2′-deoxycytidine-induced cytotoxicity and limb reduction defects in the mouse. Teratology 65(4):180-190 (Pubitemid 34242117)
47. Shea CM, Edgar CM, Einhorn TA, Gerstenfeld LC (2003) BMP treatment of C3H10T1/2 mesenchymal stem cells induces both chondrogenesis and osteogenesis. J Cell Biochem 90(6):1112-1127 (Pubitemid 37485049)
48. Silber J, Jacobsen A, Ozawa T, Harinath G, Pedraza A, Sander C, Holland EC, Huse JT (2012) miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PLoS ONE 7(3):e33844
49. Sokal RR, Rohlf FJ (1995) Biometry: the principles and practice of statistics in biological research. New York (NY). Freeman 3:1995
50. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, Meister G, Hermeking H (2007) Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6(13):1586-1593 (Pubitemid 47327945)
51. Toder V, Carp H, Fein A, Torchinsky A (2002) The role of pro- and anti-apoptotic molecular interactions in embryonic maldevelopment. Am J Reprod Immunol 48(4):235-244
52. Torchinsky A, Toder V (2010) Mechanisms of the embryo's response to embryopathic stressors: a focus on p53. J Reprod Immunol 85(1):76-80
53. Torchinsky A, Fein A, Toder V (1995) Immunoteratology: I. MHC involvement in the embryo response to teratogens in mice. Am J Reprod Immunol 34(5):288-298
54. Torchinsky A, Fein A, Toder V (2005) Teratogen-induced apoptotic cell death: does the apoptotic machinery act as a protector of embryos exposed to teratogens? Birth Defects Res C Embryo Today 75(4):353-361 (Pubitemid 43244623)
55. Torchinsky A, Mizrahi L, Savion S, Shahar R, Toder V, Kobyliansky E (2012) Bone loss in adult offspring induced by low-dose exposure to teratogens. J Bone Miner Metab 30(3):270-280
56. Tulasne D, Foveau B (2008) The shadow of death on the MET tyrosine kinase receptor. Cell Death Differ 15(3):427-434 (Pubitemid 351267293)
57. Vousden KH, Prives C (2009) Blinded by the light: the growing complexity of p53. Cell 137(3):413-431
58. Wei J, Shi Y, Zheng L, Zhou B, Inose H, Wang J, Guo XE, Grosschedl R, Karsenty G (2012) miR-34 s inhibit osteoblast proliferation and differentiation in the mouse by targeting SATB2. J Cell Biol 197(4):509-521
59. Wise LD, Beck SL, Beltrame D, Beyer BK, Chahoud I, Clark RL, Clark R, Druga AM, Feuston MH, Guittin P, Henwood SM, Kimmel CA, Lindstrom P, Palmer AK, Petrere JA, Solomon HM, Yasuda M, York RG (1997) Terminology of developmental abnormalities in common laboratory mammals (version 1). Teratology 55(4):249-292 (Pubitemid 27331350)
60. Zhu WG, Hileman T, Ke Y, Wang P, Lu S, Duan W, Dai Z, Tong T, Villalona-Calero MA, Plass C, Otterson GA (2004) 5-aza-2′-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem 279(15):15161-15166 (Pubitemid 38618911)